Skip to main content
Seema Nayak, MD, Infectious Disease, Baltimore, MD, National Institutes of Health Clinical Center

SeemaU.NayakMD

Infectious Disease Baltimore, MD

Director, Office of Clinical Research Resources, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Dr. Nayak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Nayak's full profile

Already have an account?

Education & Training

  • George Washington University
    George Washington UniversityFellowship, Infectious Disease, 2009 - 2011
  • George Washington University School of Medicine and Health Sciences
    George Washington University School of Medicine and Health SciencesNon Degree, Global Health, 2009 - 2010
  • University of Maryland
    University of MarylandResidency, Internal Medicine, 2006 - 2009
  • George Washington University School of Medicine and Health Sciences
    George Washington University School of Medicine and Health SciencesClass of 2006
  • George Washington University
    George Washington UniversityB.S., Biology, 1998 - 2002
  • George Washington University
    George Washington UniversityB.A., Religion, 1998 - 2002

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2011 - 2025
  • DC State Medical License
    DC State Medical License 2009 - 2024
  • VA State Medical License
    VA State Medical License 2009 - 2011
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

  • Junior Faculty Leadership Program Johns Hopkins University, 2015
  • Emerging Women's Leadership Program Johns Hopkins University, 2014
  • Alpha Omega Alpha Honor Society George Washington University School of Medicine, 2006
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Phase I Clinical Trials of DAS-181, an Inhaled Sialidase, in Healthy Adults  
    Zenilman JM, Fuchs EJ, Hendrix CW, Radebaugh C, Jurao R, NayakSU, Hamilton RG, McLeod Griffiss J, Antiviral Research, 1/1/2015
  • Safety and Pharmacokinetics of XOMA 3AB, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin A  
    Nayak SU, Griffiss JM, McKenzie R, Fuchs EJ, Jurao RA, An AT, Ahene A, Tomic M, Hendrix CW, Zenilman JM, Antimicrobial Agents and Chemotherapy, 1/1/2014
  • No Nephrotoxicity for Tenofovir Combined with Ritonavir in Treatment of Adult HIV Infection  
    Nayak S, Amdur R, Kan V, Journal of AIDS and HIV Research, 1/1/2014
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • "Safety and Pharmacokinetics of a Novel Co-mixture of Three Monoclonal Antibodies Against Botulism in Healthy Subjects."
    SU Nayak, R McKenzie, E Fuchs, R Jurao, J Goodwin, E Zimmerman, AAn, C Hendrix, Q Liu, J Ma, A Ahene, Y Espinosa, M Griffiss, J Zenilman, Abstracts of the 11th Annual Meeting of the American Society of Microbiology Biodefense and Emerging Diseases, Washington, DC, 1/1/2013
  • "Renal Function in HIV-Infected Veterans on Tenofovir with and without Ritonavir."
    SU Nayak, M Czarnogorski, R Amdur, VL Kan, Abstracts of the 49th Annual Meeting of the Infectious Diseases Society of America, Boston, MA, 1/1/2011
  • "Prevalence of Asymptomatic Bacterial Sexually Transmitted Infections in Hospitalized Human Immunodeficiency Virus Patients in Baltimore City."
    SU Nayak, AC Hodowanec, LE Fantry, Abstracts of the 48th Annual Meeting of the Infectious Diseases Society of America, Vancouver, BC, 1/21/2010
  • Join now to see all

Lectures

  • STIs 
    Good Samaritan Hospital, Baltimore, MD - 1/21/2015
  • Mycobacteria 
    Johns Hopkins Bayview Medical Center, Baltimore, MD - 1/10/2014
  • Pre-Exposure Prophylaxis 
    Johns Hopkins Bayview Medical Center, Baltimore, MD - 1/7/2014
  • Join now to see all

Press Mentions

  • “Remdesivir for COVID-19” Study Accidentally Proved Effectiveness of Hydroxychloroquine
    “Remdesivir for COVID-19” Study Accidentally Proved Effectiveness of HydroxychloroquineOctober 26th, 2020

Grant Support

  • Phase I Clinical Trial Unit for Therapeutics Against Infectious DiseasesNIH-NIAID2015–2018
  • HIV Prevention Training of ProvidersCDC2015–2016
  • HIV Prevention Training of ProvidersCDC2014–2015
  • Sexually Transmitted Infections Clinical Trials Grant, Task Area 1, Task Order 4NIH-NIAID2014–2015
  • Phase I Clinical Trial Unit for Therapeutics Against Infectious DiseasesNIH-NIAID2008–2015
  • HIV Prevention Training of ProvidersCDC2014
  • HIV Prevention Training of ProvidersCDC2013–2014
  • AIDS Education and Training CenterUniversity of Pittsburgh/Health Resources and Services Administration2011–2013

Committees

  • Advisory Committee, Scientific Advisory Committee, 26C Contract, Clinical Research Management 2013 - 2018

Hospital Affiliations